Accessibility Menu
Olema Pharmaceuticals logo

Olema Pharmaceuticals

(NASDAQ) OLMA

Current Price$14.98
Market Cap$1.27B
Since IPO (2020)-70%
5 Year-66%
1 Year+264%
1 Month-34%

Olema Pharmaceuticals Financials at a Glance

Market Cap

$1.27B

Revenue (TTM)

$0.00

Net Income (TTM)

$162.45M

EPS (TTM)

$-1.86

P/E Ratio

-7.81

Dividend

$0.00

Beta (Volatility)

1.43 (Average)

Price

$14.98

Volume

72,947

Open

$14.55

Previous Close

$14.98

Daily Range

$14.42 - $15.04

52-Week Range

$2.86 - $36.26

OLMA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Olema Pharmaceuticals

Industry

Biotechnology

Employees

131

CEO

Sean P. Bohen, MD, PhD

Headquarters

San Francisco, CA 94107, US

OLMA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-37%

Return on Capital

-37%

Return on Assets

-30%

Earnings Yield

-12.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.27B

Shares Outstanding

87.16M

Volume

72.95K

Short Interest

0.00%

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$178.70M

EBITDA

$178.21M

Operating Cash Flow

$146.72M

Capital Expenditure

$0.00

Free Cash Flow

$146.72M

Cash & ST Invst.

$505.44M

Total Debt

$1.19M

Olema Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$187.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.27B

N/A

Market Cap/Employee

$13.22M

N/A

Employees

96

N/A

Net Income

$46.06M

-37.2%

EBITDA

$49.90M

-36.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$504.24M

+16.5%

Accounts Receivable

$4.06M

+91.3%

Inventory

$0.00

N/A

Long Term Debt

$69.00K

-73.2%

Short Term Debt

$1.12M

-4.1%

Return on Assets

-30.45%

N/A

Return on Invested Capital

-37.10%

N/A

Free Cash Flow

$38.33M

-45.8%

Operating Cash Flow

$38.33M

-45.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRVSCorvus Pharmaceuticals, Inc.
$14.09+0.07%
VTYXVentyx Biosciences, Inc.
$14.00+0.00%
KALVKalVista Pharmaceuticals, Inc.
$16.43+6.07%
LXRXLexicon Pharmaceuticals, Inc.
$1.62+3.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%
QQQInvesco QQQ Trust
$593.02-0.00%

Questions About OLMA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.